24-Apr-2025 3:18 PM CST - Morningstar Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance Looking ahead, Gilead Sciences cut its full-year earnings outlook to $5.65 to $6.05 a share from a prior range of $5.95 to $6.35 a share. Analysts had been expecting full-year earnings of $6.22. The company left its adjusted earnings expectations unchanged at $7.70 to $8.10 a share.
24-Apr-2025 3:02 PM CST - Business Wire Gilead Sciences Announces First Quarter 2025 Financial Results #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations. Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management, said Daniel ODay, Gileads Chairman and Chief Executive Officer. Our base business grew 4% year-over-year, primarily led by Biktarvys continued strength, and we announced positive topline Phase 3 results for Trodelvy plus
24-Apr-2025 3:02 PM CST - Yahoo Finance Gilead Sciences Announces First Quarter 2025 Financial Results (Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,
23-Apr-2025 10:08 AM CST - Seeking Alpha Gilead Sciences Q1 2025 Earnings Preview Gilead Sciences Q1 earnings report is due April 24. Explore forecasts on revenue growth, EPS expectations, HIV pipeline updates, and policy impact insights.
23-Apr-2025 9:02 AM CST - Benzinga 3GILD : Exploring Gilead Sciences's Earnings Expectations Analysts have given Gilead Sciences a total of 15 ratings, with the consensus rating being Outperform. The average one-year price target is $117.07, indicating a potential 10.96% upside.
17-Apr-2025 12:07 PM CST - Yahoo Finance Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings? Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.
15-Apr-2025 4:05 AM CST - Yahoo Finance 3 Reasons GILD is Risky and 1 Stock to Buy Instead In a sliding market, Gilead Sciences has defied the odds, trading up to $106.42 per share. Its 24% gain since October 2024 has outpaced the S&P 500's 6.9% drop. This was partly due to its solid quarterly results,
Latest GILD Trades by Congress Members
31-MAR-2025 - Jefferson Shreve, IN (District 6) purchased between $15,001 and $50,000.
24-Apr-2025 3:18 PM CST - Morningstar Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance Looking ahead, Gilead Sciences cut its full-year earnings outlook to $5.65 to $6.05 a share from a prior range of $5.95 to $6.35 a share. Analysts had been expecting full-year earnings of $6.22. The company left its adjusted earnings expectations unchanged at $7.70 to $8.10 a share.
24-Apr-2025 3:02 PM CST - Business Wire Gilead Sciences Announces First Quarter 2025 Financial Results #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations. Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management, said Daniel ODay, Gileads Chairman and Chief Executive Officer. Our base business grew 4% year-over-year, primarily led by Biktarvys continued strength, and we announced positive topline Phase 3 results for Trodelvy plus
24-Apr-2025 3:02 PM CST - Yahoo Finance Gilead Sciences Announces First Quarter 2025 Financial Results (Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,
23-Apr-2025 10:08 AM CST - Seeking Alpha Gilead Sciences Q1 2025 Earnings Preview Gilead Sciences Q1 earnings report is due April 24. Explore forecasts on revenue growth, EPS expectations, HIV pipeline updates, and policy impact insights.
23-Apr-2025 9:02 AM CST - Benzinga 3GILD : Exploring Gilead Sciences's Earnings Expectations Analysts have given Gilead Sciences a total of 15 ratings, with the consensus rating being Outperform. The average one-year price target is $117.07, indicating a potential 10.96% upside.
17-Apr-2025 12:07 PM CST - Yahoo Finance Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings? Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.
15-Apr-2025 4:05 AM CST - Yahoo Finance 3 Reasons GILD is Risky and 1 Stock to Buy Instead In a sliding market, Gilead Sciences has defied the odds, trading up to $106.42 per share. Its 24% gain since October 2024 has outpaced the S&P 500's 6.9% drop. This was partly due to its solid quarterly results,
